

Press Release



For Immediate Release

Contact: Jeff Hamilton, NMA
Jeff.hamilton0675@gmail.com
David O'Hagan, Esperovax CEO
dohagan@esperovax.com

Northern Michigan Angels Invest in Michigan-based Esperovax

[Traverse City, MI – August 10, 2020] Northern Michigan Angels (NMA) has invested \$117,500 in Esperovax (<https://esperovax.com/>), a biotechnology company based in Plymouth, Michigan. The company has developed a novel oral vaccine platform that will enable large-scale production and distribution of vaccines at a fraction of the cost of current injection-based treatments.

Esperovax is currently in pre-clinical studies of its oral COVID-19 vaccine. Plans exist to apply its technology to an oral flu vaccine and other much-needed biologic treatments.

Vaccination is the most effective method for reducing and preventing human disease. Unfortunately, many vaccinations today can only be delivered through direct injection by a healthcare professional, which limits the number of patients that can be treated.

Injectable vaccines are expensive to produce, difficult to distribute, and potentially painful to administer, which complicates large-scale, global treatment programs. Esperovax looks to become the global leader in oral tablet/capsule vaccinations for some of the world's deadliest treatable diseases by leveraging its new oral vaccine platform.

Their oral vaccines will enable administration of billions of prescription-based doses annually, that can be delivered by mail and taken orally by the consumer without intervention by healthcare professionals. This platform will lead to the significant expansion of vaccination for the most vulnerable and in need, at a fraction of the cost for current methods.

"The NMA investment into Esperovax has significantly accelerated our plans to demonstrate the utility of our oral biologicals platform. We look forward to the continued support and guidance that the NMA team provides to our growing Company", said David O'Hagan, CEO of Esperovax.

About Esperovax (<https://esperovax.com/>)

Esperovax is a pre-clinical-stage, privately-held biotechnology company focused on developing vaccines and other biologic treatments using its proprietary oral delivery platform. Esperovax has developed a proprietary method for bioengineering probiotic yeast to deliver continuous and high concentrations of vaccine antigen in the gut. These antigens are delivered in the form of enveloped virus-like particles (eVLPs) right to the lymphoid tissue of the small intestine, inducing strong immune protection.

*****Continued*****

Press Release



David O'Hagan-Ph.D., Esperovax Founder, President and CEO

About Northern Michigan Angels (<https://www.northernmichiganangels.com/>)

Northern Michigan Angels is a 501 c(6) non-profit organization whose mission is to help grow the economic base of the region through investment in scalable early stage companies, and to provide members a compelling financial return on their time commitment and invested capital. Since its founding in 2012 NMA members have invested over \$5.5M in 35 early stage companies, several located in Traverse City, MI. Investments have been in companies representing a broad range of industries, all located in the State of Michigan.

***** END *****